disease. â€  When there were no published studies, we relied on the clinical experience of the panelists, which was designated very-low-quality evidence. available low-quality evidence is inconclusive regarding the efficacy of OSMs in management of PsA, whereas there is moderatequality evidence of the benefits of TNFi biologics, in particular regarding their impact on the prevention of disease progression and joint damage. In making their recommendation, the panel recognized the cost